Retatrutide: The Triple Peptide for Weight Loss That Changed the Game

Semaglutide changed the game for weight loss. Tirzepatide raised it to a new level. And now comes Retatrutide, setting the bar even higher.

Retatrutide is the first peptide to act through three mechanisms simultaneously. In early clinical trials it shows up to 24% weight loss, more than any other available peptide. And although it is still undergoing trials, it has already attracted enormous attention from the research community.

In this article we will explain what makes Retatrutide different, how its three mechanisms work, and what we know so far.

What is Retatrutide?

Retatrutide was developed by Eli Lilly, the same company that created Tirzepatide (Mounjaro). You can think of it as the next step in the evolution:

Semaglutide (2017): acts through 1 pathway (GLP-1)
Tirzepatide (2022): acts through 2 pathways (GLP-1 + GIP)
Retatrutide (in development): acts through 3 pathways (GLP-1 + GIP + glucagon)

Each successive generation adds a new mechanism. And each shows better results than the previous one.

The three mechanisms: how they work together

Let's look at what each of the three pathways does:

Pathway 1: GLP-1 (appetite control)

The same mechanism as Semaglutide. It tells the brain "I'm full," slows gastric emptying, and reduces appetite. This is the foundation shared by all three generations of weight-loss peptides.

Pathway 2: GIP (better food processing)

The same mechanism that Tirzepatide added. GIP helps the body process food more efficiently, improves insulin sensitivity, and enhances the effect of GLP-1. The GLP-1 + GIP combination is why Tirzepatide is stronger than Semaglutide.

Pathway 3: Glucagon (direct fat burning)

This is what's new. Glucagon does something that neither GLP-1 nor GIP does: it tells the liver and fat cells directly to "break down fat and turn it into energy."

With Semaglutide and Tirzepatide, the body loses weight mainly because it eats less. With Retatrutide, the body loses weight both because it eats less and because it actively burns more fat. Two fronts at once.

Additional benefit: glucagon helps the liver get rid of accumulated fat. This is important for people with fatty liver (NAFLD), a condition that affects a huge percentage of people who are overweight.

What results does it show?

The data comes from a phase 2 clinical trial with 338 participants, conducted by Eli Lilly:

Up to 24.2% weight loss over 48 weeks (at the highest dose)
This is the highest result published for any weight-loss peptide
For comparison: Semaglutide gives ~15%, Tirzepatide ~22%
The effect is felt early, many participants report reduced appetite as early as the first week
Significant improvement in fatty liver
Improvement in blood sugar, cholesterol, and triglycerides

The trial is phase 2, meaning the number of participants is smaller than in phase 3 trials. Phase 3 is underway and results are expected. But the early data is impressive.

Retatrutide vs Semaglutide vs Tirzepatide

Here is a direct comparison of the three:

Semaglutide: 1 mechanism, ~15% loss, FDA approved, millions of users, longest track record
Tirzepatide: 2 mechanisms, ~22% loss, FDA approved, newer, stronger
Retatrutide: 3 mechanisms, ~24% loss, in clinical trials, strongest, but not yet approved

There is a clear progression: each generation is more effective. But with Retatrutide, keep in mind that it is newer and the data is still accumulating.

Side effects

The side effects are similar to those of Semaglutide and Tirzepatide, since all three act through GLP-1:

Nausea (most common at the beginning, usually resolves within 2-4 weeks)
Diarrhea or constipation
Reduced appetite (which is also the goal)
Mild stomach upset

In the trials, most side effects were mild to moderate. A slow dose increase helps minimize them, just as with Semaglutide and Tirzepatide.

How is it taken?

Retatrutide is injected once a week with a pen, just like Semaglutide and Tirzepatide. The protocol includes a slow dose increase:

Starting dose: 1mg/week
Increase every 4 weeks
Target dose: 8-12mg/week (according to the trials)

The injection is subcutaneous (abdomen, thigh, or upper arm). The needle is thin, and the process is identical to the other GLP-1 pens.

Who is Retatrutide suitable for?

People who want the strongest available weight-loss peptide
People who have already tried Semaglutide or Tirzepatide and want something more effective
People with fatty liver, for whom the glucagon mechanism is particularly beneficial
People who are comfortable with the fact that the product is still in clinical trials

If you prefer a fully approved product with a long track record, Semaglutide or Tirzepatide are more suitable. If you want the newest and strongest, Retatrutide is the choice.

Frequently Asked Questions

Is Retatrutide approved?

Not yet. It is currently in phase 3 clinical trials. Eli Lilly is working toward approval, but no final date has been announced. As a research peptide, however, it is available.

Is it safer than Semaglutide?

The safety profile is similar. Side effects are similar (gastrointestinal). Semaglutide has the advantage of a longer track record and more data. Retatrutide is newer, but the data so far does not show additional risks.

Can I switch from Semaglutide/Tirzepatide to Retatrutide?

Yes. If your current peptide is not giving sufficient results, you can switch. Start at the lowest dose (1mg) and increase slowly, even if you were on high doses of another peptide.

Can I combine it with other peptides?

Do not combine with Semaglutide or Tirzepatide (overlapping mechanisms). You can add 5-Amino-1MQ (a different fat-burning pathway), MOTS-C (cellular energy), or Ipamorelin (sleep and recovery).

Conclusion

Retatrutide represents the next generation of weight-loss peptides. The triple mechanism (GLP-1 + GIP + glucagon) delivers the strongest results published so far. For people who want maximum effect and are comfortable with a newer product, it is the most promising option on the market.

→ See Retatrutide at Peptolux